Solventum (NYSE:SOLV) Price Target Raised to $79.00

Solventum (NYSE:SOLV) had its target price increased by stock analysts at UBS Group from $77.00 to $79.00 in a research note issued on Monday,Benzinga reports. The firm presently has a “neutral” rating on the stock. UBS Group’s target price would indicate a potential upside of 9.65% from the company’s current price.

A number of other research analysts have also issued reports on SOLV. Wall Street Zen lowered shares of Solventum from a “strong-buy” rating to a “buy” rating in a report on Tuesday, September 9th. Jefferies Financial Group initiated coverage on shares of Solventum in a research note on Thursday, September 11th. They issued a “hold” rating and a $80.00 target price for the company. Zacks Research raised Solventum from a “hold” rating to a “strong-buy” rating in a research note on Monday, September 15th. Morgan Stanley upgraded Solventum from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $80.00 to $103.00 in a report on Tuesday, July 15th. Finally, Wells Fargo & Company lifted their price objective on Solventum from $79.00 to $82.00 and gave the company an “equal weight” rating in a research report on Monday, September 15th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $85.56.

Solventum Price Performance

SOLV traded up $0.53 during trading on Monday, reaching $72.05. 569,236 shares of the stock were exchanged, compared to its average volume of 1,071,628. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.50 and a quick ratio of 1.14. The company has a market capitalization of $12.50 billion, a price-to-earnings ratio of 8.30, a P/E/G ratio of 2.88 and a beta of 0.49. Solventum has a 1 year low of $60.70 and a 1 year high of $85.92. The business’s 50 day moving average price is $71.97 and its two-hundred day moving average price is $72.48.

Solventum (NYSE:SOLV) last issued its quarterly earnings data on Thursday, November 6th. The company reported $1.50 earnings per share for the quarter, topping analysts’ consensus estimates of $1.43 by $0.07. Solventum had a net margin of 18.13% and a return on equity of 28.01%. The business had revenue of $2.10 billion during the quarter, compared to analysts’ expectations of $2.05 billion. During the same period last year, the company posted $1.64 EPS. The company’s revenue was up .7% on a year-over-year basis. Solventum has set its FY 2025 guidance at 5.980-6.080 EPS. As a group, equities research analysts anticipate that Solventum will post 6.58 earnings per share for the current year.

Institutional Investors Weigh In On Solventum

Several institutional investors have recently bought and sold shares of the business. Envestnet Asset Management Inc. increased its holdings in Solventum by 7.1% during the 1st quarter. Envestnet Asset Management Inc. now owns 193,510 shares of the company’s stock worth $14,714,000 after purchasing an additional 12,881 shares during the last quarter. Allworth Financial LP lifted its position in shares of Solventum by 8.1% in the 1st quarter. Allworth Financial LP now owns 4,529 shares of the company’s stock worth $344,000 after buying an additional 339 shares during the last quarter. Cerity Partners LLC lifted its holdings in Solventum by 2.8% in the first quarter. Cerity Partners LLC now owns 47,466 shares of the company’s stock worth $3,609,000 after acquiring an additional 1,294 shares during the last quarter. Xponance Inc. lifted its holdings in shares of Solventum by 1.1% in the 1st quarter. Xponance Inc. now owns 21,245 shares of the company’s stock worth $1,615,000 after purchasing an additional 231 shares during the last quarter. Finally, Diversify Wealth Management LLC boosted its holdings in shares of Solventum by 12.4% during the first quarter. Diversify Wealth Management LLC now owns 3,860 shares of the company’s stock valued at $294,000 after acquiring an additional 425 shares during the period.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.